Regeneron's lead counsel was Jonathan D. Polkes of White & Case LLP.

Sanofi and Regeneron are motivated to transform the treatment paradigm ... while putting sustainability and social responsibility at the center of our ambitions. For more information, visit www.sanofi ...

In Singapore, Dupixent is the first biologic medicine approved to treat these COPD patients. The prevalence of COPD is estimated to be around 6% of the general population [1], and it ranks as a ...

Regeneron Pharmaceuticals recently reported earnings for Q1 2025 with a revenue drop to $3,029 million compared to the prior year, though net income increased, reflecting robust profitability with ...

This is the second year Top Workplaces are being considered for the social responsibility award locally. Fire Dawgs Junk Removal won the award last year. Over the years, leadership and employees ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other worst ...

Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion ...

Naturally, when evaluating a new potential employer – or a current one – how much money you make and whether health insurance and retirement are part of the package tend to be deciding factors.

We think investors are encouraged by the vagueness of the order and the significant room for negotiations. We sell different types of products and services to both investment professionals and ...

Truth Social, the social media network owned by Trump Media, has denied it is launching a memecoin following circulating rumors on social media. “Contrary to rumors, Truth Social is not ...

The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by Citigroup on May 14, 2025. The analyst firm set a price target for $700.00 expecting REGN to rise to within 12 ...